Sugammadex and oral contraceptives.

Journal

Current opinion in anaesthesiology

ISSN: 1473-6500

Titre abrégé: Curr Opin Anaesthesiol

Pays: United States

ID NLM: 8813436

Informations de publication

Date de publication:
04 Jun 2024

Historique:

medline: 6 6 2024

pubmed: 6 6 2024

entrez: 6 6 2024

Statut: aheadofprint

Résumé

This review article explores the evidence regarding sugammadex (MSD Australia) and its potential interaction with hormonal contraceptives. The impact of recent clinical trials and review articles is examined. Recent clinical data suggest that the interaction between sugammadex and estrogen and progesterone concentrations may not be clinically significant and may confer some protection against ovulation. There are no clinical trials reporting interactions between sugammadex and the exogenous hormonal compounds found in oral contraceptive pills. The method of contraception is an important consideration, as sugammadex theoretically affects oral and nonoral, and combined versus single agent methods differently. Two large retrospective database studies have reported two cases of pregnancy postoperatively in patients on hormonal contraceptives whose anesthetic included sugammadex. Strong clinical evidence to support or refute claims of a significant impact of sugammadex on contraceptive efficacy in women on contraception is lacking. The existing evidence does not suggest a basis for concern regarding the impact of sugammadex on contraception in the perioperative setting.

Identifiants

DOI: 10.1097/ACO.0000000000001397 PMID: 38841921

pubmed: 38841921

doi: 10.1097/ACO.0000000000001397

pii: 00001503-990000000-00199

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Murphy G. The development and regulatory history of sugammadex in the United States. Anesthesia Patient Safety Foundation Newsletter 2016; 30:5.

Australian Product Information Bridion (sugammadex) Solution for Injection [package insert on the internet]. Merck Sharp & Dohme (Australia) Pty Ltd; 2008 [updated 8 February 2021]. https://rss.medsinfo.com.au/mk/pi.cfm?product=mkpbridi. [Accessed February 10 2024].

Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 41:266–270.

Dalton J, Van Hasselt G. Sugammadex – time of onset: nine months. Anaesthesia 2015; 71:115–116.

Passi N, Mutebi M, Tan M, Oliver C. Contraceptive failure and sugammadex administration: a single centre survey and audit of professional knowledge and practice. Br J Anaesth 2023; 130:e412–e414.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 May 29. Sugammadex. https://www.ncbi.nlm.nih.gov/books/NBK470263/. [Accessed February 10 2024].

Patel N. The need for teaching regarding sugammadex in the preoperative area. J Perianesth Nurs 2023; 38:823–824.

Bajaj S, Das S, Munjal M, Chatterjee N. Contraception advice to patients following sugammadex. Indian J Anaesth 2023; 67: (suppl 3): S292.

Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011; 31:101–111.

Mabbot V & Storey P. Australian Statistics on Medicines 2025, Table 1 [Data file]. Sydney, NSW: Pharmaceutical Benefits Division; 2016. https://www.pbs.gov.au/info/statistics/asm/asm-2015. [Accessed February 17 2024].

[Investigator unknown]. Prescription cost analysis (PCA) – financial year 2022/23 [Data file]. NHS Business Services Authority (NHSBSA) Data warehouse: Newburn Riverside (Newcastle upon Tyne); 2023. https://opendata.nhsbsa.net/dataset/prescription-cost-analysis-pca-annual-statistics. [Accessed February 21 2024].

Kane S. The Top 200 of 2021 [Internet]. [place unknown]: ClinCalc LLC; 2024 [updated 1 January 2024]. https://clincalc.com/DrugStats/Top200Drugs.aspx. [Accessed February 21 2024].

Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA 2021; 326:2507–2518.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 November 24. Oral contraceptive pills. https://www.ncbi.nlm.nih.gov/books/NBK430882/. [Accessed February 10 2024].

Attia A, Ibrahim M, Abou-Setta A. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adher 2013; 7:777–785.

U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Application Number 022225Orig1s000 Clinical Pharmacology and Biopharmaceutics Review(s): NDA 22-225. Reference ID 3721520. [Internet]. Silver Spring: U.S Food and Drug Administration; 2014 Oct 22. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000ClinPharmR.pdf. [Accessed February 10 2024].

Kuhnz W, Pfeffer M, al-Yacoub G. Protein binding of the contraceptive steroids gestodene, 3-ket0-desogestrel and ethinylestradiol in human serum. J Steroid Biochem 1990; 35:313–318.

Australian Product Information Implanon NXT (etonogestrel) Subdermal Implant [package insert on the internet]. Organon Pharma (Australia) Pty Ltd; 2010 [updated 4 December 2023]. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02693-3&d=20240217172310101. [Accessed February 17 2024].

The Faculty of Sexual & Reproductive Healthcare. FSRH CEU guidance recommended actions after incorrect use of combined hormonal contraception (e.g. late or missed pills, ring or patch). [Internet]. London: The Faculty of Sexual & Reproductive Healthcare; 2020 March 16 [updated 2021 July]. https://www.fsrh.org/documents/fsrh-ceu-guidance-recommended-actions-after-incorrect-use-of/#:∼:text=If%20a%20woman%20uses%20CHC,contraceptive%20methods%20.(including%20LARC). [Accessed February 10 2024].

The Faculty of Sexual & Reproductive Healthcare. FSRH Guideline Progesterone-only Pills. [Internet]. London: The Faculty of Sexual & Reproductive Healthcare; 2023 August [updated 2023 July 17]. https://www.fsrh.org/documents/cec-guideline-pop/. [Accessed February 10 2024].

Devoy T, Hunter M, Smith N. A prospective observational study of the effects of sugammadex on peri-operative oestrogen and progesterone levels in women who take hormonal contraception. Anaesthesia 2023; 78:180–187.

Gunduz Gul G, Ozer A, Demirel I, et al. The effect of sugammadex on steroid hormones: a randonmized control study. J Clin Anesth 2016; 34:62–67.

Lazowitz A, Dindinger E, Aguirre N, Sheeder J. Pre and postoperative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. J Anesth 2020; 34:294–297.

Hodge C, Myers A, Ceneviva G, et al. Retrospective analysis of sugammadex use in adolescent females on progestin-containing contraceptives. J Pediatr Adolesc Gynecol 2023; 36:459–464.

Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397–404.

Polis C, Bradley S, Bankole A, et al. Typical-use contraceptive failure rates in 43 countries with Demographic and Healthy Survey data: summary of detailed report. Contraception 2016; 94:11–17.

Do W, Cho A. What we need to know and do on sugammadex usage in pregnant and lactating women and those on hormonal contraceptives. Anesth Pain Med (Seoul) 2023; 18:114–122.

Noguchi S, Iwasaki H, Shiko Y, et al. Fetal outcomes with and without the use of sugammadex in pregnant patients undergoing nonobstetric surgery: a multicenter retrospective study. Int J Obstet Anesth 2023; 53:103620.

Richardson M, Raymond B. Sugammadex administration in pregnant women and in women of reproductive potential: a narrative review. Anesth Analg 2020; 130:1628–1637.

Sanchez K, Sanchez R, Khallouq B, Ellis D. Perioperative care of transgender and gender-diverse patients: a biopsychosocial approach. Anesth Analg 2023; 137:234–426.

Lim B, Won Y, Kim H. The effect of dexamethasone on sugammadex reversal of rocuronium-induced neuromuscular blockade in surgical patients undergoing general anesthesia. Medicine (Baltimore) 2021; 100:e23992.